c-Jun N-terminal Kinase (JNK) is Required for Survival and Proliferation of B-lymphoma Cells by Gururajan, Murali et al.
University of Kentucky
UKnowledge
Microbiology, Immunology, and Molecular
Genetics Faculty Publications
Microbiology, Immunology, and Molecular
Genetics
8-15-2005
c-Jun N-terminal Kinase ( JNK) is Required for
Survival and Proliferation of B-lymphoma Cells
Murali Gururajan
University of Kentucky
Roger Chui
University of Kentucky, rgchui2@uky.edu
Anbu K. Karuppannan
University of Kentucky
Jiyuan Ke
University of Kentucky, jiyuan.ke@vai.org
C. Darrell Jennings
University of Kentucky, cdjenn@uky.edu
See next page for additional authors
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/microbio_facpub
Part of the Medical Immunology Commons, Medical Microbiology Commons, and the
Molecular Genetics Commons
This Article is brought to you for free and open access by the Microbiology, Immunology, and Molecular Genetics at UKnowledge. It has been accepted
for inclusion in Microbiology, Immunology, and Molecular Genetics Faculty Publications by an authorized administrator of UKnowledge. For more
information, please contact UKnowledge@lsv.uky.edu.
Repository Citation
Gururajan, Murali; Chui, Roger; Karuppannan, Anbu K.; Ke, Jiyuan; Jennings, C. Darrell; and Bondada, Subbarao, "c-Jun N-terminal
Kinase ( JNK) is Required for Survival and Proliferation of B-lymphoma Cells" (2005). Microbiology, Immunology, and Molecular
Genetics Faculty Publications. 131.
https://uknowledge.uky.edu/microbio_facpub/131
Authors
Murali Gururajan, Roger Chui, Anbu K. Karuppannan, Jiyuan Ke, C. Darrell Jennings, and Subbarao Bondada
c-Jun N-terminal Kinase ( JNK) is Required for Survival and Proliferation of B-lymphoma Cells
Notes/Citation Information
Published in Blood, v. 106, no. 4, p. 1382-1391.
This research was originally published in Blood. Murali Gururajan, Roger Chui, Anbu K. Karuppannan, Jiyuan
Ke, C. Darrell Jennings and Subbarao Bondada. c-Jun N-terminal kinase ( JNK) is required for survival and
proliferation of B-lymphoma cells. Blood. 2005;106:1382-1391. © 2005 the American Society of Hematology.
The copyright holder has granted the permission for posting the article here.
Digital Object Identifier (DOI)
https://doi.org/10.1182/blood-2004-10-3819
This article is available at UKnowledge: https://uknowledge.uky.edu/microbio_facpub/131
NEOPLASIA
c-Jun N-terminal kinase (JNK) is required for survival and proliferation
of B-lymphoma cells
Murali Gururajan, Roger Chui, Anbu K. Karuppannan, Jiyuan Ke, C. Darrell Jennings, and Subbarao Bondada
Several primary murine and human B
lymphomas and cell lines were found to
constitutively express high levels of the
activated form of c-jun N-terminal kinase
(JNK), a member of the mitogen-activated
protein (MAP) kinase family. Proliferation
of murine B lymphomas CH31, CH12.Lx,
BKS-2, and WEHI-231 and the human B
lymphomas BJAB, RAMOS, RAJI, OCI-
Ly7, and OCI-Ly10 was strongly inhibited
by SP600125, an anthrapyrazolone inhibi-
tor of JNK, in a dose-dependent manner.
The lymphoma cells underwent apopto-
sis and arrested at the G2/M phase of cell
cycle. Furthermore, JNK-specific small
interfering RNA (siRNA) inhibited the
growth of both murine and human B
lymphomas. Thus in the B-lymphoma
model, JNK appears to have a unique
prosurvival role. Survival signals pro-
vided by CD40 and interleukin-10 (IL-10)
together reversed the growth inhibition
induced by the JNK inhibitor. c-Myc pro-
tein levels were reduced in the presence
of both SP600125 and JNK-specific siRNA,
and CD40 ligation restored c-Myc levels.
Moreover, Bcl-xL rescued WEHI-231 cells
from apoptosis induced by the JNK inhib-
itor. The JNK inhibitor also reduced levels
of early growth response gene-1 (Egr-1)
protein, and overexpressing Egr-1 par-
tially rescued lymphoma cells from apo-
ptosis. Thus, JNK may act via c-Myc and
Egr-1, which were shown to be important
for B-lymphoma survival and growth.
(Blood. 2005;106:1382-1391)
© 2005 by The American Society of Hematology
Introduction
Jun N-terminal kinase (JNK; also known as stress-activated protein
kinase, SAPK) is one of the 3 major members of the mitogen-
activated protein kinase (MAPK) superfamily; the others are
extracellular signal-regulated kinase (ERK) and the p38 MAP
kinase. JNK is activated in response to certain growth factors or
stresses such as ultraviolet (UV) radiation. Stress-induced JNK
activation often leads to cell death through activation of the
mitochondrial apoptotic pathway in many cell types including
neuronal cells, prostate cancer cells, and fibroblasts.1-4 On the
contrary, it has been shown recently that JNK can promote survival
of BCR/ABL-transformed leukemic cells.5 Triggering the JNK
pathway in vitro with a BCR-ABL tyrosine kinase led to a dramatic
increase in B-cell transformation. Moreover, it was shown that JNK
is required for interleukin-3 (IL-3)–mediated cell survival through
its ability to phosphorylate and inactive the proapoptotic Bcl-2
family protein BAD.6 JNK protein kinases are coded for by 3
genes, Jnk1, Jnk2, and Jnk3. Jnk1 and Jnk2 are the more widely
expressed isoforms of JNK. Jnk3 is limited in expression, restricted
primarily to the brain, heart, and testis. JNK is activated by
upstream MAPK kinases, MKK7 and MKK4.7-9 Activated JNK
phosphorylates and activates its major substrate c-jun as well as
several other transcription factors and proteins required for cell
survival, proliferation, transformation, and cell death.10
The dual role of JNK in both apoptotic and survival signaling
pathways indicates that the functional role of JNK is complex. The
biologic outcome of JNK activation depends upon the cellular
context, time course of activation, and the balance between the
ability of JNK to signal both apoptosis and cell survival. The
complexity of the cellular response to JNK activation can be
illustrated by the diverse actions of a proinflammatory cytokine
tumor necrosis factor alpha (TNF-). Sustained activation of
JNK correlates with TNF-induced apoptosis of rat mesangial
cells.11 On the other hand, JNK1 and JNK2 double knock-out
fibroblasts are more sensitive to TNF-induced apoptosis com-
pared with wild-type fibroblasts, suggesting a prosurvival role
for JNK signaling in these cells.12 Recent findings that MKK7
(an upstream activator of JNK) knock-out hepatocytes fail to
proliferate and that mouse embryo fibroblasts that lack MKK7
undergo cellular senescence and G2/M growth arrest further
support a role for JNK in cell-cycle progression.13
The role of JNK during primary B-lymphocyte growth
responses still awaits complete illumination. Signaling through
CD72, CD40, or B-cell receptor (BCR) ligation induces activa-
tion of MAP kinases, such as JNK, in primary splenic B
cells.14-16 However, no defect in BCR- or CD72-induced prolif-
eration is observed in B cells from JNK1/ or JNK2/ mice.14
This is probably due to a redundancy of function between the 2
isoforms, as JNK1 and JNK2 double knock outs exhibit
embryonic lethality.17 In T cells, JNK2 is required for the
differentiation of CD4 T cells to T helper 1 (Th1) cells, and
impaired interferon gamma (IFN-) production is observed in T
cells from JNK2/ mice.18 Using a dominant-negative mutant
of TRAF2 (TNF receptor associated factor-2), it was shown that
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TRAF2 provides antiapoptotic signals by activating JNK follow-
ing cross-linking of TNF receptor superfamily members in
lymphocytes.19
Extensive work by several groups has established that MAP
kinase pathways play critical roles in the pathogenesis of various
hematologic malignancies, providing new molecular targets for
future therapeutic approaches.20-22 Thus, inhibition of JNK activa-
tion with the pharmacologic JNK inhibitor SP600125 induces
growth arrest in myeloma cell lines.23 Certain follicular lymphomas
express constitutively the active form of p38 MAPK, and its
inhibition with SB203580, the pharmacologic inhibitor, induces
growth arrest and apoptosis.24 There is also evidence implicating
abnormal expression of c-Jun, which is a downstream effector of
the JNK pathway, in the proliferation of malignant Hodgkin
lymphoma cells.25 Gene expression profiling of diffuse large B-cell
lymphoma (DLBCL) revealed enhanced expression of JNK mRNA
in at least 60% of the samples.26 In this context, it will be
interesting to study the role of JNK MAPK in the growth regulation
of B-cell lymphomas.
Here we demonstrate that JNK is constitutively activated in
several B-lymphoma cell lines and primary lymphoma samples but
not resting B cells. Using SP600125, as well as siRNA to knock
down JNK activity, herein we show that JNK activation is required
for primary B-cell proliferation in response to BCR cross-linking,
and that basal JNK activity is required for the growth of a number
of B lymphomas, including follicular, Burkitt, and DLBCLs.
Materials and methods
Reagents
SP600125 (Anthra[1,9-cd]pyrazol-6(2H)-one), an anthrapyrazolone inhibitor of
JNK and a gift from Dr B. Bennett (Celgene, San Diego, CA), was dissolved in
dimethyl sulfoxide (DMSO) and was then diluted to 2 mM in culture media as
needed. Inhibitors of the ERK MAPK (PD98059 and U0126) and p38 MAPK
(SB203580) were obtained from Calbiochem (San Diego, CA). Phospho-specific
antibodies against JNKs (Thr183/Tyr185), ERKs (Thr202/Tyr204), and c-jun
(Ser63) were obtained from Cell Signaling Technologies (Beverly, MA).
Antibodies to JNK1, ERK, early growth response gene-1 (Egr-1, C-19), and
c-Myc were obtained from Santa Cruz Biotechnologies (Santa Cruz, CA).
Monoclonal anti–-actin antibody was obtained from Sigma (St Louis, MO).
The 1C10 (anti-CD40) hybridoma was a gift from Dr M. Howard (Corixa,
Redwood City, CA). Recombinant human IL-10 and murine IL-4, IL-5, IL-6, and
TNF- were obtained from R&D systems (Minneapolis, MN); and recombinant
human IL-2, from the National Cancer Institute (Frederick, MD).
Cells and mice
The panel of B-cell lymphomas included cells of murine and human origin.
Of murine origin were BKS-2, CH12.LX, CH31, WEHI-231, and the
WEHI-231 Bcl-xL, and those of human origin included BJAB, Ramos,
RAJI, and the human DLBCL cell lines OCI-Ly7 and OCI-Ly10. Cells from
human lymphomas were obtained anonymously from discarded samples
submitted for flow cytometry through an institutional review board
(IRB)–approved protocol. The immature B-lymphoma cell line BKS-2 was
isolated and maintained in vivo as splenic tumor in our laboratory.27 Female
CBA/N (X-linked immunodeficient [Xid]) mice were obtained from
Jackson Lab (Bar Harbor, ME). Mice were kept in microisolator cages in
our American Association for Laboratory Animal Accreditation and Certifi-
cation–approved rodent facility. BKS-2 B-lymphoma cells obtained from
the spleens of CBA/N mice were depleted of T cells with a cocktail of
anti–T-cell antibodies and complement as described.28 Normal splenic B
cells were prepared according to procedures described previously.14 B cells
were isolated from human peripheral blood mononuclear cells (PBMCs) by
previously described procedures.29
Proliferation assay
BKS-2, BJAB, and Ramos cells were cultured in IF-12 medium (1:1
mixture of Iscove modified Dulbecco medium [IMDM] and Ham F12
(GIBCO, Grand Island, NY)  10% fetal calf serum [FCS; Atlanta
Biologicals, Norcross, GA]). DLBCL cell lines were cultured in IMDM 
20% normal human plasma. All other cell lines were cultured in RPMI
supplemented with 10% FCS. To measure proliferation, 2  104 cells were
cultured in 200 L medium supplemented with 10% FCS. Cultures were
treated with varying doses of SP600125, PD68059, or SB203580, or an
equivalent concentration of DMSO. After 44 hours, the cultures were
pulsed for 4 hours with 1 Ci (0.037 MBq) [3H] thymidine (DuPont/NEN,
Boston, MA), and the cells were harvested onto filter mats using a cell
harvester (Packard, Meriden, CT). The levels of radionucleotide incorpora-
tion were measured with a Matrix 96 -radiation counter (Packard,
Downers Grove, IL). Human B-cell cultures were pulsed at 66 hours and
harvested 6 hours later. Results were presented as arithmetic mean of
triplicate cultures plus or minus SE, and statistical significance of different
treatments was evaluated by the Student t test. Percentage of control
response was defined as counts per minute (cpm) in the treated group/cpm
in the untreated group  100.
Western blotting and flow cytometry
BKS-2 B-lymphoma cells, harvested from CBA/N mice and depleted of T
cells, were treated with SP600125 at concentrations from 5 to 15 M in
1-mL cultures of 1  106 cells in 6-well plates (Corning/Costar, Cam-
bridge, MA). Cell lysates were prepared in 1  sodium dodecyl sulfate
(SDS) sample buffer or 1% Triton-X 100 as described earlier14,30 and were
subjected to SDS–polyacrylamide gel electrophoresis (PAGE) and Western
blot analysis. The Western blots were analyzed by probing the membrane
using various primary antibodies followed by horseradish peroxidase
(HRP)–conjugated secondary antibodies (Santa Cruz Biotechnologies). The
blots were developed with Pico Chemiluminescence substrate (Pierce
Biotechnology, Rockford, IL) and exposed to Kodak X-O mat film, which
was scanned with a flat-bed scanner (UMAX Technologies, Hsinchu,
Taiwan). Alternatively, the blots were scanned by a Kodak Image Station
2000RT (Eastman Kodak, New Haven, CT). For reprobing, membranes
were stripped using a solution containing 62.5 mM Tris (tris(hydroxy-
methyl)aminomethane)–HCl, 2% SDS, and 100 mM -mercaptoethanol at
65°C for 20 minutes. The relative integrated optical density (OD) of the
protein bands was estimated using Scion Image software (Scion). Band
intensities were normalized by dividing the intensity of phosphorylated
protein by that of total protein in case of MAPK or by dividing protein of
interest to -actin. For flow cytometry, 1  106 cells were stained with
B220–fluorescein isothiocyanate (FITC), annexin V–FITC, or biotinylated
anti–intercellular adhesion molecule-1 (ICAM-1)  allophycocyanin (APC)–
avidin (BD PharMingen, San Diego, CA).
Apoptosis and cell-cycle analysis
The cell-cycle status and apoptosis were analyzed using 2 methods:
propidium iodide (PI) and Hoechst 33342 staining. Cultured B-
lymphoma cells (1  106/2mL) were stained with 1 g B220-FITC and
then fixed in ethanol for at least 1 hour at 4°C, after which cells were
incubated in a mixture of 1 g/mL PI (Sigma) and 25 g/mL RNase A
(Sigma) at 37°C for at least 30 seconds. Hoechst 33342 staining was
performed at 37°C (Molecular Probes, Eugene, OR) as described
earlier.31 The level of PI or Hoechst 33342 fluorescence was measured
with a MoFlo flow cytometer (DakoCytomation, Fort Collins, CO).
Cells in the sub-G1 region were considered apoptotic.
In vitro kinase assay
To measure JNK activity, 200 L of cell lysates were incubated with 20 L
of c-jun fusion protein beads overnight, and then kinase assay was
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performed per the manufacturer’s instructions (Cell Signaling Technology).
The reaction was carried out for 30 seconds at 30°C and was stopped by
boiling the samples in 4  SDS sample buffer. Levels of phospho–c-jun
were measured by Western blot as described in “Western blotting and flow
cytometry.”
Transfection of siRNA and plasmids into B-lymphoma cells
For transfection of siRNA, cells were washed and resuspended in Opti-
MEM (low-serum medium; GIBCO, Grand Island, NY). Cells were
electroporated with the green fluorescent protein (GFP) plasmid (pEGFP-
N1) and the siRNA (control or JNK specific) at 250 mV, 960 F, and 200 
with a Gene Pulser electroporator (BioRad, Hercules, CA). Three days after
transfection, GFP cells were sorted by a fluorescence-activated cell sorter
(FACS) MoFlo flow cytometer (DakoCytomation, Fort Collins, CO) and
plated. Cell proliferation was measured at 24 hours and 48 hours after
sorting, while some cells were lysed for Western blot. The target sequence
for JNK-specific siRNA is 5	-AAAAAGAATGTCCTACCTTCT-3	, which
is specific for both mice and humans.32 Both JNK-specific and control
siRNA were obtained from Qiagen (Valencia, CA). For Egr-1 overexpres-
sion studies, BKS-2 B-lymphoma cells were transfected with GFP alone
(pEGFP-N1) or cotransfected with GFP and Egr-1 expression vector
(pBX-Egr) by electroporation as described earlier in this section.33 Two
days later, cells were treated with 5 M SP600125. Forty-eight hours after
treatment, cells were analyzed for cell cycle and apoptosis.
In vivo studies
Female CBA/N mice were administered intravenously with 10  106
BKS-2 B-lymphoma cells on day 0. From day 1, mice were injected
intraperitoneally either with 40 mg/kg body weight SP600125 (JNK
inhibitor) or the vehicle (DMSO) alternate days for 10 days. On day 11,
mice were killed and the number of nucleated cells was determined.
Results
Inhibition of JNK causes a dose-dependent reduction
in primary splenic B-cell proliferation
To test if JNK was necessary for proliferation of primary B cells,
splenic B cells were stimulated with antibodies to BCR in the
presence of varying concentrations of SP600125, the pharmaco-
logic JNK inhibitor.34 A dose-dependent reduction in the prolifera-
tion of primary splenic B cells in response to BCR cross-linking
was observed (Figure 1A). Supplementation with IL-4 did not
reverse the SP600125-mediated inhibition of BCR-induced B-cell
proliferation, although a small recovery was seen at low doses of
the inhibitor (Figure 1A). We also observed a reduction in
BCR-induced proliferative response of B cells from human periph-
eral blood upon JNK inhibition (Figure 1B). These data suggest
that JNK is downstream of BCR-induced signaling pathways that
lead to B-cell clonal expansion.
B-lymphoma cells constitutively express the activated form of
JNK and its major substrate c-jun, and inhibition of basal JNK
activity causes a dose-dependent reduction in their proliferation
Next, we determined if JNK is constitutively activated in B-
lymphoma cells that proliferate in the absence of BCR or other
mitogenic signals. JNK (Figure 2Ai-iii) and its major substrate
c-jun (Figure 2Aiv) were found to be constitutively phosphorylated
in a variety of B-lymphoma cell lines and primary tumors of both
murine and human origin (a total of 18 samples), whereas resting
murine or human B cells contained little or no phosphorylated JNK
(pJNK; Figure 2A). The prostate cancer lines LNCaP and PC-3 did
not express the activated form of JNK, despite containing large
amounts of the unphosphorylated form of JNK (Figure 2A third
panel). This basal JNK activity was necessary for proliferation of
B-lymphoma cells since treatment with varying concentrations of
SP600125 induced a dose-dependent reduction in B-lymphoma
proliferation, while the vehicle DMSO had minimal effects (Figure
2B-J). The BKS-2 B-lymphoma cells (follicular type) exhibited a
90% decrease in basal proliferation when treated with 10 M
SP600125. This appeared to be specific to the JNK inhibitor since
no effect was observed when treated with the ERK inhibitor
PD98059 or UO126 (data not shown) in this concentration range
(Figure 2B). Growth of the human Burkitt lymphoma cell line
BJAB was also reduced, showing a 70% decrease in basal
proliferation compared with control when treated with SP600125,
but showed no change in proliferation when treated with DMSO,
PD98059, or SB203580, a p38 MAPK inhibitor (Figure 2C).
Figure 2D-J shows the effect of SP600125 on additional murine B
lymphomas (CH12-LX and CH31 [B-1–cell lymphomas] and
WEHI-231 [an immature lymphoma]), human B lymphomas
(Ramos and RAJI, 2 lines of Burkitt origin), and 2 in vitro–adapted
DLBCL lines (OCI-Ly7 and OCI-Ly10). Similar results were also
obtained with A20 (a mature B-cell lymphoma) and several
Epstein-Barr virus (EBV)–transformed lymphoblastoid cell lines
(data not shown), demonstrating that JNK was essential for
proliferation of a variety of B-lymphoma cells. On the other hand,
prostate cancer cell line PC-3 was relatively resistant to JNK
inhibitor (Figure 2K) and did not express constitutively activated
JNK (Figure 2A third panel). However, apoptosis was induced in
PC-3 cells by a proteasome inhibitor (MG132) that prevents
NF-
B activation.
JNK inhibition induces growth arrest and apoptosis
in B-lymphoma cells
We investigated whether the decrease in proliferation was due to
growth arrest, apoptosis, or both. Cell-cycle analysis performed by
staining DNA with PI or Hoechst yielded similar results, both
demonstrating an increase in sub G1 population, an indicator of
apoptotic cells (Figure 3A top panel). The apoptotic population in
BKS-2 increased from 4%  1% to 19%  2% when treated with
SP600125. We also measured apoptosis by annexin V staining.
Figure 1. Inhibition of JNK activity using SP600125 causes a reduction in
BCR-induced proliferation of primary splenic B cells. (A) Splenic B cells from
DBA/2 mice were treated with 50 g/mL anti-IgM alone ( and - - -) or 10 g/mL
anti-IgM  IL-4 20 U/mL (Œ and —) in the presence or absence of indicated doses of
SP600125 for 2 days. Results were expressed as percentage of control response
(mean  SD of triplicate cultures) when compared with cells that were not treated
with SP600125 (the actual counts are 81 032  12 381 for anti-IgM 50 g/mL,
16 489  3815 for anti-IgM plus IL-4). (B) Human peripheral blood B cells were
treated with 10 g/mL anti-IgM in the absence () or presence () of indicated doses
of SP600125 for 3 days. The actual counts were 4942  61 for anti-IgM (10 g/mL) 
IL-2 (100 U/mL) and 4717  208 for DMSO equivalent. Proliferation was measured
as described in “Materials and methods.” Results are presented as mean  SE of
triplicate cultures. Results are representative of 4 experiments in panel A and of 2
experiments in panel B.
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Annexin V–positive cells increased from 13%  1% to 29%  2%
when BKS-2 B lymphomas were treated with 10 M SP600125
(Figure 3A bottom panel). A similar increase in apoptotic cells was
observed in WEHI-231, another murine B lymphoma (PI staining,
Figure 3B top panel; or annexin V staining, Figure 3B bottom
panel). Of interest, WEHI-231 and CH31 B-lymphoma cells not
only exhibit enhanced apoptosis, but also undergo G2/M arrest
when stained with PI (Figure 3B; data not shown). Similar G2/M
arrest was also seen in BKS-2 lymphoma at higher concentrations
of SP600125. The majority of B lymphomas of human origin
predominantly underwent G2/M growth arrest with fewer apoptotic
cells (Table 1).
Growth inhibitory effects of JNK inhibition can be overcome
by addition of -CD40 and IL-10
To test whether the effects of JNK inhibition by SP600125 could be
reversed, we treated lymphoma cells with a combination of
anti-CD40 and IL-10. It is known that ligation of CD40 on the
surface of primary B cells and some B-lymphoma cells can
enhance their proliferation. IL-10, produced by many B-cell
lymphomas, has been shown to promote survival of B lympho-
mas.35-37 A combination of anti-CD40 and IL-10 was able to
overcome growth inhibition caused by SP600125 (Figure 3C).
Treatment with IL-10 alone did not reverse SP600125-induced
Figure 2. Constitutive expression of activated JNK and phospho–c-jun in B lymphomas and the effect of MAPK inhibitors on the growth of murine and human
B-lymphoma cells. (A) Murine and human B-lymphoma cell lines (i), primary B lymphoma isolated from mouse (ii), and primary B-lymphoma samples from human
patients (iii) expressed phosphorylated form of JNK constitutively with little expression by normal splenic B cells, normal peripheral blood human B cells, and prostate
cancer cells (LNCaP and PC-3). A variety of B-lymphoma cell lines and tumors from both murine and human origin express phosphorylated form of c-jun constitutively
(iv). Mouse primary tumors are spontaneous B lymphomas from aged mice (tumor nos. 1 to 7) and B lymphomas isolated from E-Myc transgenic mice. Human primary
B lymphomas include small-cell lymphoma (SCL), large-cell lymphoma (LCL), follicular cell lymphoma (FCL), Burkitt lymphoma (BL), and marginal zone lymphoma
(MZL), which are characterized by flow cytometry. (B) BKS-2 B-lymphoma cells were cultured for 48 hours with vehicle (DMSO) alone or with indicated concentrations of
SP600125 or PD98059. Results were expressed as percentage of basal proliferation (mean  SE of triplicate cultures) when compared with cells that were not treated
with any inhibitor. The actual counts are 61 449  2636 for the untreated cells. (C) BJAB B-lymphoma cells were cultured for 48 hours with vehicle (DMSO) alone, or the
indicated concentrations of SP600125, PD98059, or SB203580. The actual counts are 119 333  7118 for the medium. Panels D, E, F, G, and H represent the effect of
SP600125 on basal proliferation of CH12.LX, WEHI-231, CH31, Ramos, and RAJI B-lymphoma cells, respectively; panels I and J, of OCI-Ly7 and OCI-Ly10 DLBCL
cells, respectively. For D-G and I-J, f indicates SP600125; , DMSO equivalents. (K) Annexin V staining of prostate cancer cell line PC-3 in the presence or absence of
varying concentrations of SP600125 for 24 hours. MG132 is used as a positive control, which is a proteasome inhibitor. Results are presented as means  SE of
triplicate cultures. *P  .05 when comparing response with SP600125 to solvent or medium-only treatment. Results are representative of 3 experiments.
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apoptosis, whereas treatment with -CD40 alone was only partially
effective. This combination is unique since TNF-, IL-1, IL-2,
IL-4, IL-5, and IL-6 failed to rescue BKS-2 cells from SP600125-
induced growth inhibition, nor did they enhance the partial effect of
anti-CD40 (data not shown).
SP600125 inhibits phosphorylation of c-jun but not ERK
or p38 MAPK
To verify the specificity of the JNK inhibitor SP600125, we
performed an in vitro kinase assay using c-jun fusion protein beads
and cold adenosine triphosphate (ATP). Cells were treated for 6
hours with SP600125, and total cell lysates were subjected to in
vitro kinase assay as described in “Materials and methods.” There
is a dose-dependent reduction in the phosphorylation of c-jun in the
presence of SP600125 (Figure 4A). Consistent with the presence of
constitutively activated pJNK in several B lymphomas shown in
Figure 2, phosphorylated c-jun was detected in untreated cells
(Figure 4B) and treatment with SP600125 for 6 hours reduced the
levels of phospho–c-jun. Similar results were obtained with the
murine B-lymphoma cell lines. Treatment with SP600125 did not
reduce the levels of pERK or phospho-p38 as shown in Figure 4C.
However, SP600125 partially inhibits phosphorylation of JNK
(Figure 4C), which is consistent with published results.38-40
Knocking down JNK by RNA interference causes a decrease
in proliferation and an increase in apoptosis of B-lymphoma
cells but not prostate cancer cells
As an alternate approach to test the significance of JNK for
lymphoma growth, we targeted JNK using siRNA that can recog-
nize a common sequence in both JNK1 and JNK2 from both mice
and humans.32 As shown in Figure 5A, there was a 90% decrease in
basal proliferation in BKS-2 B-lymphoma cells transfected with
JNK-specific siRNA compared with control siRNA–transfected
Figure 3. Inhibition of JNK activity induces growth arrest and apoptosis in B-lymphoma cells and can be overcome by the addition of anti-CD40 and IL-10. (A) BKS-2
murine B-lymphoma cells were cultured in 6-well plates at 1  106 cells/well in the presence of 0 to 10 M doses of SP600125. Two days later, cell-cycle analysis was
performed on these cultured cells by PI staining as described in “Materials and methods” (top). (Bottom) Histogram of annexin V–positive cells gated on PI-negative population
in the presence or absence of 10 M SP600125. (B, top) Histogram representation of PI staining of WEHI-231 B lymphoma in the presence or absence of the JNK inhibitor.
(Bottom) Histogram of annexin V–positive cells gated on PI-negative population in the presence or absence of 10 M SP600125. In top panels, M1, M2, M3, and M4 indicate
cells in sub-G1, G1, S, and G2/M phases of cell cycle. In bottom panels, percentages indicate annexin V–positive cells. (C) BKS-2 B-lymphoma cells were incubated with
different doses of SP600125 in the presence or absence of -CD40 (1:1000 dilution of ascites) and IL-10 (50 U/mL), or vehicle (DMSO) alone for 2 days, and proliferation was
measured as described in “Materials and methods.” Results were expressed as percentage of control response (mean  SE of triplicate cultures) when compared with cells
that were not treated with any inhibitor. Experiments were done 2 to 3 times with similar results.
Table 1. Cell-cycle analysis of human Burkitt B-lymphoma cells
treated with SP600125 inhibitor for 48 hours
Cell line
Sub-G1
(apoptotic) G0/G1 S G2/M
BJAB (medium) 1  0 42  0 25  0 32  0
BJAB (SP600125, 20 M) 3  0 18  1 15  1 64  2
RAJI (medium) 6  1 39  0 38  1 16  0
RAJI (SP600125, 20 M) 13  1 22  1 30  2 33  2
Values presented are percentage of cells in each phase of cell cycle. Phase of
cell cycle was determined by flow cytometric analysis of propidium iodide-stained
cells. Results are presented as means  SE of triplicate cultures. Experiments were
performed 2 to 3 times with similar outcome.
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cells. We observed a similar growth inhibition in the WEHI-231
B-lymphoma cells (Figure 5B) and BJAB (data not shown). Figure
5C showed that there was more apoptosis and a significant decrease
in S phase in BKS-2 and WEHI-231 cells transfected with
JNK-specific siRNA compared with control. Western analysis
showed that siRNA treatment reduced JNK protein levels in both
BKS-2 and WEHI-231 lymphoma cells (Figure 5D). Inhibiting
constitutive JNK activity by 2 different approaches, namely
SP600125 and siRNA, suggested a prosurvival role for JNK in
B-lymphoma cells. On the other hand, treating prostate cancer cell
line PC-3, which lacks constitutive JNK expression (Figure 2A
third panel), with JNK-specific siRNA did not induce apoptosis as
measured by PI analysis (Figure 5C).
Cell-cycle regulator c-Myc is down-regulated upon inhibition
of JNK signaling in B-lymphoma cells
Several studies have shown that c-Myc is an important oncoprotein
that is overexpressed in many human and murine B lymphomas.
Dysregulated c-Myc expression was critical for proliferation of
such lymphomas, and transgenic expression of c-Myc in B cells
resulted in B-lymphoma development.41-47 In WEHI-231 and
BKS-2 cells, BCR cross-linking led to down-regulation of c-Myc,
resulting in growth inhibition that was overcome by c-Myc
overexpression.28,48 So, we investigated whether levels of c-Myc
were affected by the JNK inhibitor. Western analysis of lysates
obtained from WEHI-231 B lymphoma treated with 10 M
SP600125 showed a reduction in c-Myc protein levels as early as 3
hours that persisted even at 24 hours compared with untreated cells
(Figure 6A). When JNK was inhibited with JNK-specific siRNA,
an 87% reduction in c-Myc protein levels was observed in
Figure 4. SP600125 inhibits c-jun phosphorylation but not phosphorylation of
ERK or p38 MAPK. (A) WEHI-231 B-lymphoma cells were incubated with medium or
treated with 10 M SP600125 for 6 hours. In vitro kinase assays were performed on
the cell lysates and subsequently analyzed by immunoblotting with an antibody to
phospho–c-jun. (B) BJAB B-lymphoma cells were incubated with medium or treated
with 10 M SP600125 for 6 hours. Cell lysates were analyzed by immunoblotting with
an antibody to phospho–c-jun. (C) BKS-2 B-lymphoma cells were incubated with
medium or treated with 10 M SP600125 for 6 hours. Cell lysates were analyzed by
immunoblotting with an antibody to phospho-JNK, phospho-ERK, or phospho-p38.
All the blots that were probed for phosphokinases were then stripped and reprobed
with antibodies to total kinase or actin to correct for changes in protein loading in
different lanes. Experiments were performed 2 times with similar results.
Figure 5. Effects of JNK-specific siRNA on basal proliferation and survival of
B-lymphoma cells. (A) BKS-2 or (B) WEHI-231 B-lymphoma cells were cotrans-
fected with the GFP plasmid and siRNA (control or JNK specific). Three days later,
GFP cells were sorted by FACS and proliferation assay was performed as described
in “Materials and methods.” Results are presented as means  SE of triplicate
cultures. (C) Hoechst analysis of GFP BKS-2 and WEHI-231 B-lymphoma cells or
prostate cancer cells PC-3 cotransfected with control or JNK-specific siRNA. u
indicates G2/M; , S; o, G1; and f, sub- G1. (D) Western analysis of lysates from
control or JNK-specific siRNA–treated WEHI-231 (top) and BKS-2 cells (bottom) by
an antibody to JNK. The blots were then stripped and reprobed for -actin as a
loading control. Results are representative of 2 to 3 experiments. *P  .001 when
response with JNK siRNA is compared with control siRNA.
Figure 6. Cell-cycle regulator c-Myc and prosurvival transcription factor Egr-1
are downstream of JNK signaling in B-lymphoma cells. (A) WEHI-231 B-
lymphoma cells were incubated with medium, 10 M SP600125, and anti-CD40,
either alone or in combination for the indicated time periods. Cell lysates were
analyzed by immunoblotting with an antibody to c-Myc. The blots were then stripped
and probed with anti–-actin antibody to correct for changes in protein loading in
different lanes. (B) Immunoblotting of lysates from control or JNK-specific siRNA–
transfected WEHI-231 cells with antibodies to c-Myc and -actin. (C) BKS-2
B-lymphoma cells were incubated with medium or 10 M SP600125 for the indicated
time periods. Cell lysates were analyzed by immunoblotting with an antibody to Egr-1
and then stripped and probed for -actin. (D) WEHI-231 B-lymphoma cells were
treated with control or JNK-specific siRNA for 24 hours. Cell lysates were analyzed by
immunoblotting with an antibody to Egr-1 and then stripped and probed for -actin.
(E) Flow cytometry analysis of SP600125- or vehicle (DMSO)–treated BKS-2 cells
with an antibody to ICAM-1. Flow cytometry was performed as described in “Materials
and methods.” Numbers indicate the ratio of density of c-Myc to -actin in panels A
and B and of Egr-1 to -actin in panel C. Experiments were done 2 to 3 times with
similar results.
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WEHI-231 cells, confirming the specific effect of the JNK inhibitor
(Figure 6B). Reduced c-Myc expression was also observed in
BKS-2 and BJAB B-lymphoma cells when treated with SP600125
(data not shown). Moreover, c-Myc levels were restored by
signaling through CD40 in the presence of the JNK inhibitor
(Figure 6A) in accordance with the ability of CD40 to overcome
the JNK inhibitor–induced growth inhibition (Figure 3C).
Prosurvival transcription factor Egr-1 is down-regulated upon
JNK inhibition, and its overexpression partially protects
against apoptosis induced by the JNK inhibitor
Previous studies from our laboratory have shown that Egr-1 was
overexpressed in BKS-2 B lymphoma and that inhibition of Egr-1 using
antisense oligonucleotides specific for Egr-1 induced apoptosis.49 Based
on this finding, we hypothesized that Egr-1 might be downstream of JNK
signaling. There was a reduction in the Egr-1 protein in cells treated with
10 M SP600125 (Figure 6C) or with JNK siRNA (Figure 6D).
Moreover, the Egr-1 target gene ICAM-1 levels were slightly reduced but
in a highly reproducible manner in SP600125-treated cells (83% of
control cells; Figure 6E).50,51 Egr-1 and GFP were ectopically expressed
by cotransfection with 2 plasmids. Cell-cycle analysis of GFP-positive
cells demonstrated that Egr-1 expression partially overcame the inhibitory
effects of SP600125 (Figure 7A). Direct examination of apoptosis with
annexin V further confirmed the protective effect of Egr-1 (Figure 7B).
However, Egr-1 expression failed to reverse the G2/M arrest (Figure 7A).
Bcl-xL overcomes SP600125-induced apoptosis in WEHI-231
B-lymphoma cells
Previously, we showed that Egr-1 inhibition was accompanied by a
decrease in Bcl-xL expression in BKS-2 cells.52 Moreover, Bcl-xL is
overexpressed in some B lymphomas and can be induced by CD40
signaling.53-55 Anti-IgM–induced apoptosis of WEHI-231 cells is pre-
vented by stable expression of Bcl-xL.56 Accordingly, we found that
WEHI-231 cells that stably express Bcl-xL were resistant to apoptosis
induced by the JNK inhibitor compared with WEHI-231 cells (Figure
7C), but they continued to exhibit G2/M arrest (data not shown).
In vivo role for JNK in B-lymphoma growth regulation
Having shown that JNK plays a prosurvival role in regulating
B-lymphoma growth in vitro, we investigated the role of JNK in
vivo in our mouse model of B-lymphoma BKS-2. There was a
significant reduction in the tumor burden of drug (SP600125)–
treated but not vehicle (DMSO)–treated mice as measured by the
total splenocyte numbers (Figure 8A). Representative spleens from
both vehicle- and drug-treated mice are shown in Figure 8B.
Discussion
We reported earlier that primary splenic B cells express activated forms
of JNK when either the BCR or CD72 (a coreceptor on B cells) is
ligated, stimuli that induce normal B-cell proliferation.14 Using a
pharmacologic inhibitor, we herein show that JNK activity is essential
for BCR-induced proliferation of both normal murine splenic B cells
and peripheral blood human B cells. Furthermore, we found that many
B-lymphoma cell lines as well as primary tumor samples of both human
and murine origin constitutively express the activated form of JNK
(pJNK) and its major substrate c-jun (phospho–c-jun). This basal JNK
activity is required for B-lymphoma proliferation. Inhibition of JNK
activation with SP600125 or inhibition of JNK expression by siRNA
resulted in reduced basal proliferation of several murine B-lymphoma
cell lines, human Burkitt B-lymphoma cells, as well as human DLBCL
cell lines. Our findings for the first time demonstrate that JNK activity is
critical for B-lymphoma proliferation. In this lymphoma cell system, the
SP600125 inhibitor appeared to be highly specific to JNK since
phosphorylation of ERK and p38 MAP kinases was not affected.
Figure 7. Egr-1 partially rescues BKS-2 B-lymphoma cells from SP600125-induced apoptosis, and Bcl-xL antagonizes apoptosis induced by SP600125 in WEHI-231
B-lymphoma cells. (A) Hoechst analysis of BKS-2 cells expressing control vector (GFP alone) or Egr-1 in the presence or absence of 5 M SP600125 at 48 hours. (B) Same
as in panel A except for analysis by annexin V and PI staining for apoptotic cells. (C) PI analysis of WEHI-231 or WEHI-231 stably transfected with Bcl-xL (WEHI-Bcl-xL) in the
presence or absence of 10 M SP600125. Results are presented as means  SE of triplicate cultures. Similar results were obtained in 2 other experiments.
Figure 8. Inhibiting JNK activity with SP600125 leads to regression of B-
lymphoma growth in vivo. (A) Splenocyte numbers of mice treated with vehicle
(DMSO) or drug (SP600125). Mice were administered 10  106 BKS-2 B-lymphoma
cells on day 0 and subsequently with intraperitoneal injection of 40 mg/kg body weight
of the drug SP600125 or the vehicle (DMSO) alternate days for 10 days. Experiments
(Expt.) were performed 2 times. (B) Photograph of vehicle- and drug-treated spleen
of CBA/N mice on day 11. Horizontal bars represent means of all the numbers for all
the mice in the group.
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Moreover, SP600125 has been shown to specifically inhibit JNK
activity without altering the activity of cyclinA/cyclin-dependent kinase
(cdk), Akt, signal transducer and activator of transcription 3 (STAT3),
and p27, and several other kinases in in vitro systems.23,57,58 This is
further supported by our observations that the prostate cancer cell line
PC-3, which lacks constitutively activated JNK, is resistant to SP600125-
induced growth inhibition. Western analysis with isoform-specific
antibodies showed that both JNK1 and JNK2 are expressed in these
lymphoma cells. The relative contribution of the 2 isoforms of JNK
requires further investigation.
The growth inhibitory effect of SP600125 can be reversed by
simultaneous stimulation through anti-CD40 and IL-10. Ligation of
CD40 transmits signals that abrogate apoptosis induced by BCR ligation
in immature B-lymphoma cell lines such as WEHI-231.59 Expression of
Bcl-xL and A1 is enhanced by CD40 ligation, suggesting a role for
antiapoptotic proteins in CD40-induced B-cell survival.60-62 Accord-
ingly, we found that JNK inhibition did not induce apoptosis in
Bcl-xL–expressing WEHI-231 cells. IL-10, a pleiotropic cytokine with
anti-inflammatory properties, is a potent growth and survival factor for
malignant B cells. The New Zealand black (NZB) strain of mice
develop an age-related malignant expansion of B-1 cells with autocrine
production of IL-10. Of interest, the IL-10 knock-out mice on NZB
background do not develop malignancy, suggesting that IL-10 is a
critical factor for the progression of this B-cell–malignant disease.63 Our
data show that the growth inhibitory effects of JNK inhibition can be
rescued by signaling through both CD40 and IL-10 receptor.
We also tested the significance of 2 other MAPK family
members, including ERK and p38, in B-lymphoma growth regula-
tion. Although these B lymphomas express activated forms of ERK
constitutively, inhibition of its activity by 2 different inhibitors
PD98059 and UO126 did not affect their basal proliferation.
Moreover, the p38 inhibitor SB203580 did not inhibit the prolifera-
tion of 2 B-lymphoma cell lines tested. These data demonstrate that
ERK and p38 MAPK are not crucial for basal proliferation of
B-lymphoma cell lines BKS-2 and BJAB. However, p38 MAP
kinase has recently been shown to be activated during progression
of follicular lymphoma into DLCBL.24 Hence more B lymphomas
have to be examined for the relative importance of different MAPK
enzymes for lymphoma growth.
Decrease in proliferation can be due to increased growth arrest,
apoptosis, or both. The fact that more cells shift from S phase
toward sub-G1 phase of cell cycle in the presence of either
SP600125 or the JNK-specific siRNA in BKS-2 B-lymphoma cells
suggests that these cells undergo apoptosis. Of interest, all the
lymphoma cells undergo G2/M growth arrest in addition to
apoptosis. We also observed aneuploidy by PI analysis when
WEHI-231 and CH31 B-lymphoma cells were treated with 20 M
or more of SP600125. In fact, similar observations have been made
in multiple myeloma cells, erythroleukemic cells, and breast cancer
cells, where SP600125 induces both G2/M arrest and apopto-
sis.23,57,58 This is consistent with an increase in JNK activity during
G2/M phase of cell cycle observed in Jurkat and carcinoma
cells.64,65 The apoptosis may be secondary to G2/M arrest since
Bcl-xL expression overcomes apoptosis but not cell-cycle arrest.
Many B lymphomas overexpress c-Myc due to chromosomal
translocations, and this overexpression is important for their
proliferation and cell-cycle progression.41,42,46,48,66 JNK is known to
up-regulate c-Myc expression in response to growth factors such as
platelet-derived growth factor.67 Moreover, it has been shown that
WEHI-231 B-lymphoma cells stably transfected with c-Myc are
resistant to anti-IgM–induced growth arrest.48 We observed a
significant reduction in c-Myc protein in both SP600125- and
siRNA-treated WEHI-231 B lymphoma, suggesting that inhibition
of JNK may cause growth arrest by inhibiting c-Myc expression.
c-Myc translocation, which leads to its overexpression, is common
in Burkitt B-lymphoma cells. However, in Burkitt lymphomas,
often the c-Myc gene is translocated to the immunoglobulin
heavy-chain locus, whose expression may still be regulated by the
MAPK pathway. This may account for the growth inhibition of
these cells by the JNK inhibitor.
c-Myc expression has been shown to be cell-cycle dependent.
Elevated c-Myc levels were observed during G1 and G2/M phases
of cell cycle with moderate levels at the S phase, and c-Myc was
shown to cooperate with Ras to induce cdc2, a kinase required for
G2/M progression.68 Moreover, it was shown that drug-induced
G2/M arrest of Jurkat T cells is correlated with c-Myc down-
regulation.69 It is possible that JNK regulates c-Myc during the
G2/M phase of cell-cycle progression since MKK7 knock-out
fibroblasts in which JNK activation is compromised undergo G2/M
arrest and cellular senescence.13 Down-regulated c-Myc might
account for the G2/M arrest observed in SP600125-treated cells.
This is consistent with the protective effect of CD40, as CD40
signaling restored c-Myc levels (Figure 6).56 Moreover, our prelimi-
nary results suggest that ectopic expression of c-Myc in WEHI-231
cells overcomes the G2/M arrest induced by the JNK inhibitor.
Egr-1, an immediate early gene is overexpressed in our mouse
model of BKS-2 B lymphoma. Inhibition of Egr-1 either with the
antisense oligonucleotides specific for Egr-1 or with a retrovirus
construct that expresses a repressor of Egr-1 (WT-Egr1) inhibits the
basal proliferation of BKS-2 (M.G., J.K., and S.B., manuscript in
preparation). Moreover, the Egr-1 promoter has an activator protein
1 (AP-1) binding site, suggesting a possible role for JNK signaling
during activation of Egr-1 expression.70 Accordingly, we show that
Egr-1 protein is reduced early in SP600125- or JNK siRNA–treated
cells and is completely abrogated by 24 hours of treatment.
Moreover, ectopic expression of Egr-1 partially rescued BKS-2
B-lymphoma cells from apoptosis induced by the JNK inhibitor
SP600125. These data for the first time demonstrate that Egr-1 may
be one of the survival factors downstream of JNK signaling. It was
shown recently that in prostate cancer cells induction of p300/
cyclic adenosine monophosphate response element binding protein
(CBP) by Egr1 results in acetylation and stabilization of Egr1 and
subsequent transactivation of survival genes.71
The prosurvival role for JNK in B-lymphoma growth was further
substantiated by our in vivo studies in a mouse model of B lymphoma.
In summary, our data demonstrate for the first time that the proliferation
of primary B cells and B-lymphoma cells is dependent on JNK
activation. Patients with activated B-cell–like DLBCLs have poor
prognosis, with only 40% responding to chemotherapy.26 Our findings
suggest that targeting JNK may have some important therapeutic
implications in the treatment of B lymphomas.72
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